Contact the lab

Peptide science

Small chains.
Significant possibilities.

Some peptide medicines deliver measurable clinical benefits. Others are still being tested. Explore how they work, where the evidence is strongest, and the questions that remain.

Explore the evidence Read the sources

This overview concerns therapeutic and investigational peptides. It is not a guide to collagen supplements, dosing, or self-treatment.

Selected evidence / sources checked October 16, 2026 Scroll to explore

01 / The foundations

What makes peptides worth studying?

Conceptual blue and clear molecular chain

From sequence to question

A chain is a starting point.

  1. 01 Sequence
  2. 02 Structure
  3. 03 Biological target

Conceptual illustration, not a model of a named compound.

Peptides are short chains of amino acids. Their sequence and structure help determine how they behave. Some peptide medicines act on specific biological receptors, but the word peptide does not tell us whether a product is effective, appropriate, or safe. [1] [3] [5]

The opportunity is real: particular peptide medicines have produced meaningful clinical benefits. The scientific question is more precise than "Do peptides work?" It is which molecule, for which outcome, in which people, and with what trade-offs?

This page separates demonstrated benefits from early findings. Evidence for one molecule, formulation, or route is not automatically evidence for another.

02 / Demonstrated benefits

Where the evidence is already meaningful.

The findings, in view

Two studies. Two different questions.

Each chart compares groups within its own trial. The populations, outcomes, and chart scales differ.

SELECT

Major cardiovascular events

Observed event rates over an average 39.8 months.

Semaglutide6.5%
Placebo8.0%
0%8%

17,604 adults with established cardiovascular disease and overweight or obesity, without diabetes. The outcome combined cardiovascular death, nonfatal heart attack, or nonfatal stroke. [2]

SURMOUNT-1

Average body-weight reduction

Group averages at 72 weeks.

Tirzepatide groups15.0–20.9%
Placebo3.1%
0%25%

2,539 adults with obesity, or overweight plus a weight-related condition, without diabetes. The shaded extension shows the range across tested treatment groups, not a confidence interval. Individual results vary. [4]

Selected findings from the trials cited below. Keep benefits, adverse effects, and study limitations together.

Semaglutide

Clinical outcomes / specific population

In SELECT, 17,604 adults aged 45 or older with established cardiovascular disease and overweight or obesity, but without diabetes, were randomized to semaglutide or placebo. Over an average 39.8 months of follow-up, the primary cardiovascular outcome occurred in 6.5% versus 8.0%. That is a calculated difference of 1.5 percentage points in the observed event proportions. [2] [3]

This is evidence of benefit in the studied population, not a claim that every peptide protects the heart. Adverse events caused more treatment discontinuations with semaglutide, 16.6% versus 8.2%. The drug also has product-specific warnings and contraindications. [2] [3]

Tirzepatide

Randomized trials / defined clinical uses

In the 72-week SURMOUNT-1 trial, 2,539 adults with obesity, or overweight plus a weight-related condition, and without diabetes were studied. Average body-weight reductions ranged from 15.0% to 20.9% across the tested tirzepatide groups, compared with 3.1% with placebo. These are group averages, not promised individual results. Gastrointestinal adverse effects were common. [4]

Zepbound, a tirzepatide product, also has an FDA-approved indication for moderate to severe obstructive sleep apnea in adults with obesity, alongside a reduced-calorie diet and increased physical activity. That is a specific clinical use, not a general promise of better sleep. [5]

Teriparatide

Established medicine / bone health

Peptide medicine extends beyond weight management. Teriparatide is a parathyroid-hormone analog used for specified osteoporosis populations. In postmenopausal women with osteoporosis at high fracture risk, its approved labeling describes reductions in vertebral and nonvertebral fractures. [6]

This does not make it a general sports-injury or performance treatment. Important cautions include hypercalcemia and avoiding use in people with specified increased baseline risks for osteosarcoma, among other warnings in the full prescribing information. [6]

Curiosity with a standard

Not one promise.
A field of possibilities.

03 / Research in progress

Promising questions. Different levels of proof.

Retatrutide

Investigational / Phase 3 development

Retatrutide targets GIP, GLP-1, and glucagon receptors. Lilly's July 2026 report announced positive Phase 3 weight-loss findings in TRIUMPH-2 and TRIUMPH-3. This is a substantial clinical-development program, not merely a theory derived from cell experiments. The July report was a sponsor-reported topline announcement. Peer-reviewed results for TRIUMPH-1 (New England Journal of Medicine) and TRIUMPH-2 (The Lancet) followed in late September 2026, and Lilly has said it plans to seek FDA review in early 2027. [7] [15] [16]

FDA information checked October 16, 2026 identifies retatrutide as not a component of an FDA-approved drug. Progress in clinical development does not establish that commercially sold "research" versions are equivalent to the study medicine. [8]

BPC-157

Small human pilot / major unanswered questions

A published 2025 intravenous safety pilot observed two participants who had previously received BPC-157. No side effects were reported during that short study. This is a human observation, but it is far too small and brief to establish general safety or demonstrate faster injury recovery. [9]

FDA identifies limited safety information and potential immune-reaction and peptide-impurity concerns for compounded BPC-157. FDA now lists the earlier compounding nomination for BPC-157 as withdrawn. In July 2026, an FDA advisory committee narrowly voted to recommend BPC-157 for a compounding list. That vote is not drug approval, and FDA's published safety concerns still apply. The appropriate conclusion is that important questions remain, not that either benefit or safety has been established. [10] [17] [18]

A separate FDA compounding policy entered White House review in October 2026.

What that review does and does not mean
A microscope objective under blue light

Look at the question

What did the study actually measure?

Biological activity, safety, and patient outcomes are different questions. Keep the measured outcome beside the claim.

CJC-1295 and ipamorelin

Human pharmacology / not proven performance outcomes

Early human research has investigated growth-hormone-related responses to CJC-1295 and ipamorelin. These studies support biological activity for the formulations studied. They do not, by themselves, demonstrate improved strength, injury healing, or longevity, and they do not validate marketed combinations. [11] [12]

FDA also identifies safety concerns and limitations for these compounds. A measurable hormone response is a reason for careful research, not a substitute for patient-outcome evidence. [10]

GHK-Cu

Topical findings / route-specific interpretation

In one randomized study of skin care after laser resurfacing, 13 patients completed treatment. GHK-Cu was associated with greater patient-reported improvement in skin quality, but blinded assessments did not find superior wrinkle or overall skin improvement between groups. That distinction belongs beside the favorable result. [13]

The study tested a topical regimen. It does not establish benefits from injection or systemic "anti-aging" use. FDA notes limited human safety data for injectable GHK-Cu. [10]

TB-500

Exact molecule matters / evidence gaps

FDA's safety information specifically identifies the thymosin beta-4 fragment LKKTETQ, also called TB-500, and states that it has not identified human exposure data for drug products containing that fragment. An FDA advisory committee also voted in July 2026 to recommend TB-500 for a compounding list. That recommendation does not supply the missing human data. [10] [17] [19]

Do not treat research on a different thymosin molecule or formulation as interchangeable evidence for a product marketed as TB-500. The molecular identity and the actual intervention must match the claim.

04 / The HHL evidence standard

The finding is only part of the story.

A study through six lenses

Keep the context attached to the finding.

  1. 01Compound
  2. 02Formulation & route
  3. 03Population
  4. 04Comparison
  5. 05Measured outcome
  6. 06Follow-up

Start with the actual study. We identify the compound, formulation, route, population, comparison, measured outcome, and follow-up. A receptor response or change in a blood marker should not be relabeled as an improvement in strength, recovery, or lifespan.

Keep evidence and approval separate. A compound can have human trial evidence and still be investigational. An approved medicine also has specific indications and limitations. Neither category is a blanket recommendation for personal use. [3] [6] [8]

Keep the exact product in view. Compounded medicines can serve legitimate medical needs, but they are not FDA-approved products. Trials of a manufactured study medicine do not verify the identity, quality, or clinical performance of a different vial sold under the same ingredient name. [14] [8]

Keep legal access separate from proof. FDA approval, pharmacy compounding, and products sold for "research use" are different routes, and none of them settles the scientific question on its own. Approval follows FDA review of a specific product for a specific use. Compounded drugs are not FDA-approved, and FDA lists safety concerns for several peptides on this page, including BPC-157 and TB-500. FDA has also warned companies that sold retatrutide and other GLP-1 drugs labeled "research only" or "not for human use" to consumers. [14] [10] [8]

A policy under review is not a decision. On October 14, 2026, the White House Office of Information and Regulatory Affairs received an FDA notice titled "Interim Access Policy for Compounding Using Certain Peptides" for review. As of October 18, 2026, neither its text nor a list of covered peptides had been published. [20] The Associated Press, citing two unnamed people familiar with the plan, reported that it would temporarily let pharmacies compound some popular peptides, including BPC-157, with FDA choosing not to take enforcement action. That reporting does not name retatrutide, which FDA states cannot be used in compounding under federal law. [21] [8] A proposal under review is not FDA approval, and it does not grant current permission to compound BPC-157 or any other peptide it may cover. If a policy like this takes effect, it would change who may legally prepare a product, not what the evidence shows about whether that product is safe or effective.

Treat uncertainty honestly. Limited evidence does not prove a treatment never works. It does limit the claims we can responsibly make. A personal experience may inspire a research question, but it cannot establish that a compound caused the outcome or will do the same for someone else.

05 / Benefits and trade-offs

Benefit and safety belong together.

Biological activity can produce unwanted effects as well as useful ones. The relevant risks depend on the particular compound, preparation, route, and person. Approved peptide medicines have contraindications and warnings; experimental preparations can add unresolved safety and quality questions. [3] [6] [10] [14]

This is an educational overview, not a prescribing guide. It does not provide injection instructions, dosing schedules, stacks, cycling advice, or vendor recommendations. Decisions about medicines belong with a licensed clinician who can assess the individual situation.

The benefits that withstand scrutiny are worth explaining clearly. The unanswered questions are worth investigating honestly.

06 / Read the evidence

Sources, not slogans.

Selected primary studies and official scientific, labeling, and regulatory information, plus dated news reports of an FDA advisory vote and a pending policy review, labeled as reporting rather than FDA records. This is not an exhaustive systematic review. Sponsor reports are labeled separately from journal publications. Check current prescribing information with a qualified clinician.

  1. NHGRI. PeptideOfficial scientific glossary.
  2. New England Journal of Medicine. Semaglutide and Cardiovascular Outcomes in Obesity without DiabetesPeer-reviewed randomized trial, SELECT, 2023. doi:10.1056/NEJMoa2307563, PMID 37952131.
  3. U.S. Food and Drug Administration. FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or OverweightFDA indication announcement, March 8, 2024.
  4. New England Journal of Medicine. Tirzepatide Once Weekly for the Treatment of ObesityPeer-reviewed randomized trial, SURMOUNT-1, 2022. doi:10.1056/NEJMoa2206038, PMID 35658024.
  5. U.S. Food and Drug Administration. FDA Approves First Medication for Obstructive Sleep ApneaFDA indication announcement, December 20, 2024.
  6. DailyMed / Eli Lilly. FORTEO (teriparatide) prescribing informationFDA-approved product labeling, revised August 2026.
  7. Eli Lilly and Company. Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1CSponsor-reported topline announcement, July 23, 2026.
  8. U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight LossCurrent FDA safety and regulatory information, content current as of October 1, 2026, accessed October 16, 2026.
  9. Lee and Burgess / Alternative Therapies in Health and Medicine. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot StudyPublished human pilot, two participants, 2025. PMID 40131143.
  10. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety RisksCurrent FDA safety information, content current as of April 22, 2026, accessed October 16, 2026.
  11. Teichman et al. / Journal of Clinical Endocrinology & Metabolism. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adultsPublished randomized, placebo-controlled human pharmacology study, 2006. PMID 16352683.
  12. Gobburu et al. / Pharmaceutical Research. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteersPublished human pharmacology study, 1999. PMID 10496658.
  13. Miller et al. / Archives of Facial Plastic Surgery. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skinRandomized topical-regimen study, 2006. PMID 16847171.
  14. U.S. Food and Drug Administration. Understanding the Risks of Compounded DrugsOfficial compounding information, content current as of June 22, 2026.
  15. New England Journal of Medicine. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of ObesityPeer-reviewed randomized trial, TRIUMPH-1, published online September 2026. doi:10.1056/NEJMoa2604169, PMID 42814954.
  16. The Lancet. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2)Peer-reviewed randomized trial, published online September 2026. doi:10.1016/S0140-6736(26)01861-1, PMID 42810372.
  17. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory CommitteeOfficial FDA advisory committee meeting page; agenda included BPC-157 and TB-500.
  18. Regulatory Affairs Professionals Society. FDA advisory committee backs two controversial peptidesRegulatory news report of the committee votes, July 23, 2026. Not an FDA record; FDA has not finalized a decision as of October 16, 2026.
  19. ABC News. FDA advisers narrowly vote to add 6 peptides to a drug compounding list. What's next?News report of the committee recommendations, including TB-500, July 24, 2026. Not an FDA record.
  20. Office of Information and Regulatory Affairs. Regulatory actions currently under review: Interim Access Policy for Compounding Using Certain PeptidesOfficial review listing, RIN 0910-ZD94, stage: notice, received October 14, 2026; checked October 18, 2026. Lists the review only, not the policy text.
  21. Associated Press. Trump administration advances plan for peptide drugs favored by RFK Jr.News report, October 15, 2026. Its description of the plan relies on unnamed sources; not an FDA record.

Editorial status: sources rechecked October 16, 2026 against the primary pages and PubMed records listed above. This page has not been reviewed by a clinician. It is general information, not medical advice.

Better questions.
A clearer next step.

Suggest a topic or ask a question about the evidence presented here. This contact route is not a medical consultation service.

Contact the lab More work from the lab

Contact opens the form on our home page. We reply within 2 business days.